Clinical efficacy and tolerability of magnesium valproate as monotherapy in patients with generalised or partial epilepsy: A nonblinded study of 320 patients

Clinical Drug Investigation

Volumn 20, Issue 4, 2000, Pages 215-221

  Canger, Raffaele ^a,b   Guidolin, Loredana ^a  

^a Regional Epilepsy Centre   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VALPROATE MAGNESIUM;

ADOLESCENT; ADULT; AMENORRHEA; ARTICLE; BODY WEIGHT; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOCAL EPILEPSY; GASTROINTESTINAL SYMPTOM; GENERALIZED EPILEPSY; HEMATOLOGIC DISEASE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REMISSION; SEIZURE; SKIN DISEASE;

EID: 0033756539     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200020040-00002     Document Type: Article

References (5)

1. Fueta Y, Avoli M. Age- and magnesium-dependent efficacy of valproate. Epilepsia 1991; 32 (3): 37
2. McCollum EV, Orent ER. Effects on the rat of deprivation of magnesium. J Biol Chem 1931; 92: 30-1
3. Kruse HD, Orent ER, McCollum EV. Studies on magnesium deficiency in animals. I. Symptomatology resulting from magnesium deprivation. J Biol Chem 1932; 96: 519-39
4. Aird R, editor. The epilepsies: a critical review. New York: Raven Press, 1984
5. Slater GE, Johnston GD. Sodium valproate increases potassium conductance in Aplysia neurons. Epilepsia 1978: 19: 379-84